Amylin Rejected $3.5 billion Bid from Bristol-Myers Squibb

Bloomberg reported this morning that Bristol-Squibb Myers (NYSE: BMY) approached Amylin (NASDSAQ: AMLN) with a $3.5 billion offer or $22 per share.

Keep Reading →